Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
CTD Holdings Posts Recording of its Webinar on US Clinical Trial | ||
By: Nasdaq / GlobeNewswire - 18 Oct 2018 | Back to overview list |
|
Webinar recording is on the Company website ALACHUA, Fla., Oct. 18, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that a recording of the October 16, 2018 webinar on the Company’s US clinical trial using Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) is available HERE and on its website, www.ctd-holdings.com. Trappsol® Cyclo™ is CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin. Niemann-Pick Disease Type C is a rare and fatal genetic disease that causes cholesterol to accumulate in every cell in the body, ultimately causing cell and organ dysfunction and death. The US-based clinical trial that was the subject of the webinar uses intravenous administration of Trappsol® Cyclo™. Featured speakers on the webinar are: CTD’s Chairman and CEO, N. Scott Fine; Families wishing to have additional information on CTD’s US clinical trial are invited to contact: Dr. Caroline Hastings at chastings@mail.cho.org or Oakland Study Coordinator Allen Hodgson, Ahodgson@mail.cho.org Dr. Darius Adams, Darius.Adams@atlantichealth.org or Morristown Study Coordinator Christina Flora, Christina.Flora@atlantichealth.org Or, for CTD’s Family Liaison, Shannon Reedy at Shannon.Reedy@Hotmail.com Physicians and other healthcare professionals who would like more information about CTD’s US clinical trials, EU/Israel clinical trials, or Expanded Access programs should contact Dr. Hrynkow, at sharon.hrynkow@cyclodex.com About CTD Holdings: Safe Harbor Statement: Investor/Media Contact: Thomas Mulligan
|
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |